Lyra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Lyra Therapeutics

10/05/2022 15:07

* Lyra Therapeutics Inc  LYRA.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in March. The
mean expectation of two analysts for the quarter was for a loss
of 91 cents per share.
    * Revenue was $5.37 million​;  analysts expected $1.25
million. 
    * Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 54 cents​.
    * The mean earnings estimate of analysts had fallen by
about 22%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Lyra Therapeutics Inc shares had risen by 12.7% this
quarter and
gained 3.9% so far this year.
    * The company reported a quarterly loss of $7.01 million.
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $24.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 02:07 p.m.  ​All
figures in US dollars unless otherwise stated